Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Tango Therapeutics ( (TNGX) ) has shared an update.
On April 10, 2026, Tango Therapeutics’ board decided that Chief Financial Officer and principal financial officer Daniella Beckman would leave her roles, effective April 15, 2026, with her last day of employment recorded as May 1, 2026. On May 7, 2026, the company and Beckman executed a separation agreement that outlines compensation and equity provisions tied to her departure.
Under the agreement, Beckman will receive 12 months of severance at her current base salary, paid in equal installments, along with reimbursement of COBRA health premiums for up to a year. Tango also accelerated vesting of the stock options and restricted stock units she would have earned over the next 24 months and extended the exercise window on vested options through August 31, 2026, in exchange for her granting a general release to the company.
The most recent analyst rating on (TNGX) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Tango Therapeutics stock, see the TNGX Stock Forecast page.
Spark’s Take on TNGX Stock
According to Spark, TipRanks’ AI Analyst, TNGX is a Neutral.
The score is primarily held back by weak financial performance—large operating losses and heavy free-cash-flow burn alongside declining revenue—offset in part by strong technical momentum (price well above key moving averages with positive MACD). Corporate events are modestly supportive due to leadership and operational build-out, while valuation remains constrained by a loss-making profile and no dividend.
To see Spark’s full report on TNGX stock, click here.
More about Tango Therapeutics
Tango Therapeutics, Inc. operates in the biotechnology and biopharmaceutical industry, focusing on the discovery and development of targeted cancer therapies. The company’s work centers on precision oncology, aiming to identify and exploit specific genetic vulnerabilities in tumors to develop novel, oncology-focused treatments for patients.
Average Trading Volume: 3,375,018
Technical Sentiment Signal: Buy
Current Market Cap: $3.39B
For a thorough assessment of TNGX stock, go to TipRanks’ Stock Analysis page.